Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Touchstone Diabetes Center, Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA.
Cell Metab. 2020 Jan 7;31(1):162-173.e5. doi: 10.1016/j.cmet.2019.10.003. Epub 2019 Nov 7.
Insulin resistance is a major factor in obesity-linked type 2 diabetes. PPARγ is a master regulator of adipogenesis, and small molecule agonists, termed thiazolidinediones, are potent therapeutic insulin sensitizers. Here, we studied the role of transcriptional co-activator with PDZ-binding motif (TAZ) as a transcriptional co-repressor of PPARγ. We found that adipocyte-specific TAZ knockout (TAZ AKO) mice demonstrate a constitutively active PPARγ state. Obese TAZ AKO mice show improved glucose tolerance and insulin sensitivity compared to littermate controls. PPARγ response genes are upregulated in adipose tissue from TAZ AKO mice and adipose tissue inflammation was also decreased. In vitro and in vivo mechanistic studies revealed that the TAZ-PPARγ interaction is partially dependent on ERK-mediated Ser112 PPARγ phosphorylation. As adipocyte PPARγ Ser112 phosphorylation is increased in obesity, repression of PPARγ activity by TAZ could contribute to insulin resistance. These results identify TAZ as a new factor in the development of obesity-induced insulin resistance.
胰岛素抵抗是肥胖相关 2 型糖尿病的一个主要因素。过氧化物酶体增殖物激活受体γ (PPARγ) 是脂肪生成的主要调节因子,小分子激动剂,称为噻唑烷二酮类,是有效的治疗胰岛素增敏剂。在这里,我们研究了转录共激活因子与 PDZ 结合基序 (TAZ) 作为 PPARγ 的转录共抑制因子的作用。我们发现,脂肪细胞特异性 TAZ 敲除 (TAZ AKO) 小鼠表现出持续激活的 PPARγ 状态。与同窝对照相比,肥胖的 TAZ AKO 小鼠表现出改善的葡萄糖耐量和胰岛素敏感性。TAZ AKO 小鼠的脂肪组织中 PPARγ 反应基因上调,脂肪组织炎症也减少。体外和体内的机制研究表明,TAZ-PPARγ 相互作用部分依赖于 ERK 介导的 Ser112 PPARγ 磷酸化。由于肥胖时脂肪细胞 PPARγ Ser112 磷酸化增加,TAZ 对 PPARγ 活性的抑制可能导致胰岛素抵抗。这些结果表明 TAZ 是肥胖引起的胰岛素抵抗发展的一个新因素。